SHR-1916

SHR-1916 is a polyethylene glycol (PEG)-modified and site-mutated form of the cytokine interleukin-2 (IL-2), developed as a novel immunotherapeutic agent for cancer. It is engineered to abolish binding to the IL-2 receptor alpha subunit (IL-2Rα) and instead exerts its activity mainly through binding to IL-2 receptor beta-gamma complex (IL-2Rβγ). This design results in preferential activation of CD8+ T cells and natural killer (NK) cells, with reduced stimulation of regulatory T cells, aiming to enhance anti-tumor immune responses while minimizing side effects associated with traditional IL-2 therapies. SHR-1916 activates the JAK1-JAK3–STAT5 signaling pathway, promotes IFNγ secretion without triggering other proinflammatory cytokines, demonstrates improved pharmacokinetics due to PEGylation, and has shown significant anti-tumor efficacy in preclinical models. It is being developed primarily for solid tumors[1][3][4][6].

Other names

peg-modified/site-mutated il-2 shr-1916